Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study
By
- AMS
posted
Jan 12, 2021 04:17 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
- AMS
Added Aug 13, 2021
Blog Entry
Predictors of drug survival of biologic therapies in psoriasis patients
- AMS
Added May 13, 2020
Blog Entry
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
- AMS
Added Jan 07, 2021
Blog Entry
Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response
- AMS
Added Jun 26, 2020
Blog Entry
Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey
- AMS
Added Nov 02, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic